On 30 January 2026, Celltrion announced that it has launched Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), in major European countries, including Germany, France and Spain.
Celltrion’s launch strategy in France has involved winning bids from private hospital groups by prioritising supply stability. According to Celltrion, this has resulted in securing 80% of the French private tocilizumab market (by volume). In Spain, Celltrion secured Avtozma® contracts in regional public tenders held in the Basque Country, Madrid, and Andalucia and it was selected as the supplier by a Ministry of Health bidding agency, INGESA, for 8 regions. Celltrion is also leveraging its sales of existing products, such as Remsima SC® (infliximab) and Yuflyma® (adalimumab), to expand prescriptions to tocilizumab in European retail markets.
Avtozma® was the third tocilizumab biosimilar approved in the EU, in February 2025, following Fresenius Kabi’s Tyenne®, in both IV and SC forms in November 2023, and Biogen’s IV Tofidence® in June 2024.
Avtozma® was launched in the US in an IV formulation in October 2025, following its US approval in January 2025. It had previously been launched in Korea in June 2025. The biosimilar has also been granted marketing authorisation in a number of other regions, including as the first tocilizumab biosimilar approved in Australia (May 2025), Japan (September 2022) and New Zealand (December 2025).